AbbVie Inc. ABBV

$OCGN

ZACKS just DOUBLED DOWN on Ocugen

https://www.zacks.com/stock/news/935314/What-Makes-Ocugen-OCGN-a-New-Strong-Buy-Stock

Its not expensive and its not to late to get in ABBV has a price target of 88 from CFRA .
Earlier today investors were concerned that Allergan was going to charge more for the deal but in extended hours Allergan and ABBV released that their deal was still on for May, as is. See Seeking Alpha. BUY BUY BUY

Investors were worried Allergan was going to re negotiate their price but now in extended hours it has been determined that Allergan and Abbie will still complete the deal this May.
So BUY BUY BUY

AbbVie HIV drug being investigated as potential treatment COVID 19

https://seekingalpha.com/news/3549715

ABBV BEATS!!!
Q4 Non-GAAP EPS of $2.21 BEATS by $0.02; GAAP EPS of $1.88 BEATS by $0.05.
Revenue of $8.7B BEATS by $20M !!!
Shares +1.54% PM.

AbbVie forecasts upbeat 2020 profit.
Reuters:
https://www.cnbc.com/2020/02/07/reuters-america-abbvie-leans-on-new-treatments-to-forecast-upbeat-2020-profit.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard

ABBV BEATS!!!
Q4 Non-GAAP EPS of $2.21 BEATS by $0.02; GAAP EPS of $1.88 BEATS by $0.05.
Revenue of $8.7B BEATS by $20M !!!
Shares +1.54% PM.

AbbVie leans on new treatments to forecast upbeat 2020 profit.
Reuters:
https://www.cnbc.com/2020/02/07/reuters-america-abbvie-leans-on-new-treatments-to-forecast-upbeat-2020-profit.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard

ABBV BEATS!!!
Q4 Non-GAAP EPS of $2.21 BEATS by $0.02; GAAP EPS of $1.88 BEATS by $0.05.
Revenue of $8.7B BEATS by $20M !!!
Shares +1.54% PM.

ABBV BEATS!!

AbbVie (NYSE:ABBV): Q4 Non-GAAP EPS of $2.21 beats by $0.02; GAAP EPS of $1.88 beats by $0.05.
• Revenue of $8.7B (+4.7% Y/Y) beats by $20M.
• Shares +1.54% PM.
?????

$ABBV drug Aluvia is being used to combat the coronavirus ! BUY

$ABBV to present at the healthcare conference on Wednesday